DEXCOM INC (DXCM) Fundamental Analysis & Valuation

NASDAQ:DXCM • US2521311074

65.26 USD
-1.05 (-1.58%)
At close: Mar 12, 2026
65.29 USD
+0.03 (+0.05%)
After Hours: 3/12/2026, 8:00:02 PM

This DXCM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Taking everything into account, DXCM scores 7 out of 10 in our fundamental rating. DXCM was compared to 184 industry peers in the Health Care Equipment & Supplies industry. DXCM scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DXCM is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, DXCM could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

8

1. DXCM Profitability Analysis

1.1 Basic Checks

  • DXCM had positive earnings in the past year.
  • In the past year DXCM had a positive cash flow from operations.
  • DXCM had positive earnings in each of the past 5 years.
  • Each year in the past 5 years DXCM had a positive operating cash flow.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • With an excellent Return On Assets value of 13.19%, DXCM belongs to the best of the industry, outperforming 94.02% of the companies in the same industry.
  • DXCM has a better Return On Equity (30.46%) than 97.28% of its industry peers.
  • DXCM has a Return On Invested Capital of 18.92%. This is amongst the best in the industry. DXCM outperforms 96.74% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for DXCM is significantly above the industry average of 9.18%.
  • The 3 year average ROIC (14.59%) for DXCM is below the current ROIC(18.92%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROIC 18.92%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20 30

1.3 Margins

  • DXCM's Profit Margin of 17.94% is amongst the best of the industry. DXCM outperforms 93.48% of its industry peers.
  • In the last couple of years the Profit Margin of DXCM has declined.
  • With an excellent Operating Margin value of 21.55%, DXCM belongs to the best of the industry, outperforming 93.48% of the companies in the same industry.
  • DXCM's Operating Margin has improved in the last couple of years.
  • DXCM has a Gross Margin of 62.09%. This is in the better half of the industry: DXCM outperforms 65.22% of its industry peers.
  • DXCM's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

8

2. DXCM Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DXCM is creating value.
  • The number of shares outstanding for DXCM has been reduced compared to 1 year ago.
  • DXCM has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, DXCM has an improved debt to assets ratio.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • DXCM has an Altman-Z score of 6.35. This indicates that DXCM is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.35, DXCM belongs to the top of the industry, outperforming 85.33% of the companies in the same industry.
  • The Debt to FCF ratio of DXCM is 1.20, which is an excellent value as it means it would take DXCM, only 1.20 years of fcf income to pay off all of its debts.
  • DXCM has a better Debt to FCF ratio (1.20) than 89.67% of its industry peers.
  • DXCM has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • DXCM's Debt to Equity ratio of 0.47 is in line compared to the rest of the industry. DXCM outperforms 43.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Altman-Z 6.35
ROIC/WACC1.96
WACC9.67%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • A Current Ratio of 1.88 indicates that DXCM should not have too much problems paying its short term obligations.
  • The Current ratio of DXCM (1.88) is worse than 66.85% of its industry peers.
  • DXCM has a Quick Ratio of 1.59. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.59, DXCM is in line with its industry, outperforming 42.39% of the companies in the same industry.
  • DXCM does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.59
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

7

3. DXCM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.73% over the past year.
  • DXCM shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.29% yearly.
  • The Revenue has grown by 15.60% in the past year. This is quite good.
  • Measured over the past years, DXCM shows a quite strong growth in Revenue. The Revenue has been growing by 19.33% on average per year.
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%13.12%

3.2 Future

  • DXCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.71% yearly.
  • Based on estimates for the next years, DXCM will show a quite strong growth in Revenue. The Revenue will grow by 11.94% on average per year.
EPS Next Y36.69%
EPS Next 2Y27.75%
EPS Next 3Y24.99%
EPS Next 5Y21.71%
Revenue Next Year12.64%
Revenue Next 2Y12.51%
Revenue Next 3Y12.34%
Revenue Next 5Y11.94%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

6

4. DXCM Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 35.09, DXCM can be considered very expensive at the moment.
  • DXCM's Price/Earnings ratio is a bit cheaper when compared to the industry. DXCM is cheaper than 70.11% of the companies in the same industry.
  • DXCM's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.71.
  • A Price/Forward Earnings ratio of 25.67 indicates a quite expensive valuation of DXCM.
  • DXCM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DXCM is cheaper than 73.37% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.82. DXCM is around the same levels.
Industry RankSector Rank
PE 35.09
Fwd PE 25.67
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DXCM is valued a bit cheaper than 74.46% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DXCM is valued cheaply inside the industry as 84.78% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 23.32
EV/EBITDA 18.57
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • DXCM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • DXCM has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as DXCM's earnings are expected to grow with 24.99% in the coming years.
PEG (NY)0.96
PEG (5Y)1.82
EPS Next 2Y27.75%
EPS Next 3Y24.99%

0

5. DXCM Dividend Analysis

5.1 Amount

  • No dividends for DXCM!.
Industry RankSector Rank
Dividend Yield 0%

DXCM Fundamentals: All Metrics, Ratios and Statistics

DEXCOM INC

NASDAQ:DXCM (3/12/2026, 8:00:02 PM)

After market: 65.29 +0.03 (+0.05%)

65.26

-1.05 (-1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners100.29%
Inst Owner Change-15.36%
Ins Owners0.2%
Ins Owner Change9.49%
Market Cap25.12B
Revenue(TTM)4.66B
Net Income(TTM)836.30M
Analysts84.32
Price Target88.34 (35.37%)
Short Float %3.76%
Short Ratio2.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.4%
Min EPS beat(2)-32.12%
Max EPS beat(2)5.32%
EPS beat(4)2
Avg EPS beat(4)-6.03%
Min EPS beat(4)-32.12%
Max EPS beat(4)6.77%
EPS beat(8)5
Avg EPS beat(8)-1.11%
EPS beat(12)9
Avg EPS beat(12)9.15%
EPS beat(16)11
Avg EPS beat(16)5.86%
Revenue beat(2)1
Avg Revenue beat(2)-0.14%
Min Revenue beat(2)-0.9%
Max Revenue beat(2)0.61%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-0.9%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-1.02%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)6
Avg Revenue beat(16)-0.53%
PT rev (1m)0.69%
PT rev (3m)0.31%
EPS NQ rev (1m)-0.42%
EPS NQ rev (3m)-0.54%
EPS NY rev (1m)0.69%
EPS NY rev (3m)0.85%
Revenue NQ rev (1m)-0.33%
Revenue NQ rev (3m)-0.66%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE 35.09
Fwd PE 25.67
P/S 5.39
P/FCF 23.32
P/OCF 17.43
P/B 9.15
P/tB 9.47
EV/EBITDA 18.57
EPS(TTM)1.86
EY2.85%
EPS(NY)2.54
Fwd EY3.9%
FCF(TTM)2.8
FCFY4.29%
OCF(TTM)3.74
OCFY5.74%
SpS12.11
BVpS7.14
TBVpS6.89
PEG (NY)0.96
PEG (5Y)1.82
Graham Number17.28
Profitability
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROCE 23.93%
ROIC 18.92%
ROICexc 36.12%
ROICexgc 37.75%
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
FCFM 23.11%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
ROICexc(3y)37.89%
ROICexc(5y)31.72%
ROICexgc(3y)41.79%
ROICexgc(5y)35.48%
ROCE(3y)18.46%
ROCE(5y)14.75%
ROICexgc growth 3Y1.89%
ROICexgc growth 5Y6.96%
ROICexc growth 3Y7.33%
ROICexc growth 5Y6.44%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Debt/EBITDA 1.03
Cap/Depr 144.36%
Cap/Sales 7.8%
Interest Coverage 88.12
Cash Conversion 114.67%
Profit Quality 128.81%
Current Ratio 1.88
Quick Ratio 1.59
Altman-Z 6.35
F-Score8
WACC9.67%
ROIC/WACC1.96
Cap/Depr(3y)145.46%
Cap/Depr(5y)210.39%
Cap/Sales(3y)7.74%
Cap/Sales(5y)10.33%
Profit Quality(3y)110.93%
Profit Quality(5y)89.33%
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
EPS Next Y36.69%
EPS Next 2Y27.75%
EPS Next 3Y24.99%
EPS Next 5Y21.71%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%13.12%
Revenue Next Year12.64%
Revenue Next 2Y12.51%
Revenue Next 3Y12.34%
Revenue Next 5Y11.94%
EBIT growth 1Y53.73%
EBIT growth 3Y35.36%
EBIT growth 5Y25.41%
EBIT Next Year68.67%
EBIT Next 3Y32.44%
EBIT Next 5Y25.77%
FCF growth 1Y70.79%
FCF growth 3Y52.34%
FCF growth 5Y31.25%
OCF growth 1Y45.6%
OCF growth 3Y29.1%
OCF growth 5Y24.81%

DEXCOM INC / DXCM FAQ

Can you provide the ChartMill fundamental rating for DEXCOM INC?

ChartMill assigns a fundamental rating of 7 / 10 to DXCM.


Can you provide the valuation status for DEXCOM INC?

ChartMill assigns a valuation rating of 6 / 10 to DEXCOM INC (DXCM). This can be considered as Fairly Valued.


Can you provide the profitability details for DEXCOM INC?

DEXCOM INC (DXCM) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for DXCM stock?

The Price/Earnings (PE) ratio for DEXCOM INC (DXCM) is 35.09 and the Price/Book (PB) ratio is 9.15.